GlaxoSmithKline (NYSE:GSK), one of the big pharma companies hit hardest by the patent cliff, is trying to pull ahead by both innovating in the laboratories and innovating its research and development process. In this video, health-care analyst Max Macaluso discusses Glaxo's R&D structure and weighs in on what he expects to see from this drugmaker in 2013.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.